Navigation Links
Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial
Date:9/9/2011

For the first time, a malaria vaccine that uses the entire malaria parasite has proven safe and shown promise to produce a strong immune response in a clinical trial, according to a new study co-authored by researchers at the University of Maryland School of Medicine Center for Vaccine Development. The vaccine is unique in that it employs the entire malaria parasite, while most experimental malaria vaccines consist of just one or at most a few proteins found in the parasite. Researchers found that the vaccine the first whole parasite vaccine to be approved by the U.S. Food & Drug Administration for clinical trials could provide unprecedented immune responses against malaria when administered intravenously. The study was published online in the journal Science this week (www.sciencexpress.org).

"This is the first whole organism malaria vaccine ever produced," says Kirsten Lyke, M.D., associate professor of medicine and a research scientist at the Center for Vaccine Development at the University of Maryland School of Medicine. Dr. Lyke was one of three lead authors and two senior authors on the study, along with colleagues from the U.S. Military Malaria Vaccine Program at the Naval Medical Research Center, the Vaccine Research Center at the National Institutes of Health (NIH), and the Rockville-based biotechnology firm Sanaria, Inc., which developed and manufactured the vaccine.

"No vaccine has completely protected against malaria in a challenge trial, in which vaccinated volunteers are subjected to the bite of an infected mosquito to measure their immunity," says Dr. Lyke. "This vaccine showed strong promise. We hope that with further study it could help revolutionize the field and prevent death and illness from malaria worldwide, and be used to eliminate malaria from certain areas."

Though malaria has been largely eliminated in much of the developed world, it is still a widespread th
'/>"/>

Contact: Karen Robinson
karobinson@som.umaryland.edu
410-706-7590
University of Maryland Medical Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. MARA Fights Malaria With WaveMaker and Amazon Web Services
2. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
3. Private Sector, President's Malaria Initiative Join Forces to Strengthen Angolas Capacity to Control Mosquitoes
4. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
5. Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria
6. Malaria research must be based in Africa
7. Invisible Children's Bobby Bailey Premiers a New Documentary on Malaria
8. High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight
9. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
10. Grassroots Campaign Drives toward Ending Malaria Deaths by 2015
11. Mosquito Squad Partners with Malaria No More
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 The ... nutrition school, is pleased to announce that Arianna Huffington has ... the curriculum of the Health Coach Training Program . ... The Huffington Post, a world-renowned news and blogging site that ... is the author of fourteen books and was included on ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 Frozen shoulder ... are more likely to develop this nasty condition which occurs ... 60, and can last up to two and half years ... as frozen shoulder, and with good reason: it can render ... shirt — that is, if you aren't in too much ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... in a garden might help soothe the agitation that commonly ... at 17 past studies, British researchers found evidence that watering ... soothe some dementia patients, anxiety. The study authors cautioned ... tough subject to study -- and the evidence of a ...
(Date:7/30/2014)... three months or more as babies have a ... cardiovascular and metabolic diseases, according to research from ... Louis. , "This study shows that birthweight and ... later," said Molly W. Metzger, PhD, assistant professor ... the study with Thomas W. McDade, PhD, of ...
(Date:7/30/2014)... Lauderdale, FL (PRWEB) July 30, 2014 Everyone ... and communication for basically everyone. Whether people are looking for ... for something like a dentist, the internet is pretty much ... precisely why Sierra Dental in Lauderdale Florida is so happy ... will bring their web presence into the modern age. Whether ...
Breaking Medicine News(10 mins):Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2
... URAC CEO joins company along with ... Chief Medical Officer, ANNAPOLIS, Md., ... management leaders to head the,growing healthcare consulting and technology company. Senior management ... -- Joel V. Brill, MD, AGAF FASGE FACG CHCQM, Chief Medical ...
... Philadelphia, PA, September 20, 2007 Mark Twain boasted that it ... We now may have the beginnings of understanding why some ... are in treatment for this problem. According to statistics provided ... is the leading preventable cause of death in the United States, ...
... save years in research that aligns patients ... Fla., Sept. 20 The,H. Lee Moffitt ... Azyxxi(R),the Microsoft(R) unified health enterprise platform, to ... programs. Azyxxi will be used,to assimilate large ...
... Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation,(Nasdaq: DRRX ... CEO, will,present at the UBS Global Life Sciences ... 1:30 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ... presentation will be available by accessing,DURECT,s homepage at ...
... Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today announced that ... notional principal amount of its,6.5% senior convertible promissory notes, ... purchase warrants. This sale was effected as the,initial part ... in the,aggregate notional principal amount of up to $5 ...
... Childrens Hospital of Pittsburgh of UPMC psychiatrist Eva M. Szigethy, ... have been chosen by the director of the National Institutes ... , NIH director Elias A. Zerhouni, MD, announced today that ... in the early stages of their careers, including Dr. Szigethy ...
Cached Medicine News:Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Genetic variation affects smoking cessation treatment 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Children's Hospital of Pittsburgh psychiatrist receives prestigious NIH award 2
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
... , , ENGLEWOOD CLIFFS, ... all regular body washes caused dry skin damage. Now, ... while cleansing with body wash. Current body washes actually damage ... to the loss of critical moisture. Recognizing skin lipids require ...
Cached Medicine Technology:Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 2Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 3Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 4
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
... The current available techniques for prenatal diagnosis ... with their use a small but significant ... current standard care offers invasive prenatal baby ... risk of chromosomal or genetic abnormalities are ...
Custom Pediatric Nebulizer Assembly W/Tubing...
... the only HER-2 assessment test approved by ... for three claims: prognosis, adriamycin-based chemotherapy selection ... PathVysion is the only FISH-based DNA probe ... insert as an appropriate test to aid ...
Medicine Products: